Skip to main content
logo
Recordati Industria Chimica e Farmaceutica S.p.A. (VIE:REC)
Austria flag Austria · Delayed Price · Currency is EUR
50.40
+0.76 (1.53%)
At close: Nov 10, 2025

Revenue by Geography

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Italy Revenue
339.11M336.26M
Log In
Log In
Log In
Upgrade
International Revenue
2.14B2.01B
Log In
Log In
Log In
Upgrade

Revenue by Geography 2

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Europe Revenue
1.65B
Log In
Log In
Log In
Upgrade
Asia and Oceania Revenue
156.01M
Log In
Log In
Log In
Upgrade
America Revenue
477.46M
Log In
Log In
Log In
Upgrade
Africa Revenue
58.03M
Log In
Log In
Log In
Upgrade

Revenue Breakdown

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Specialty & Primary Care Revenue
1.53B1.51B
Log In
Log In
Log In
Upgrade
Rare Diseases Revenue
950.29M833.86M
Log In
Log In
Log In
Upgrade

Revenue Breakdown 2

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Cardiovascular Revenue
399.15M385.21M
Log In
Log In
Log In
Upgrade
Urology and Uro-Oncology Revenue
404.56M399.94M
Log In
Log In
Log In
Upgrade
Gastrointestinal Revenue
226.95M217.50M
Log In
Log In
Log In
Upgrade
Cough and Cold Revenue
129.52M137.28M
Log In
Log In
Log In
Upgrade
Other Treatment Areas Revenue
308.65M309.31M
Log In
Log In
Log In
Upgrade
Pharmaceutical Chemicals Revenue
60.62M58.47M
Log In
Log In
Log In
Upgrade
Hema-Oncology Revenue
336.71M253.23M
Log In
Log In
Log In
Upgrade
Endocrinology Revenue
347.03M321.69M
Log In
Log In
Log In
Upgrade
Metabolic and Other Areas Revenue
266.55M258.94M
Log In
Log In
Log In
Upgrade

Revenue Breakdown 3

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Pharmaceutical Chemicals Revenue
60.62M58.47M
Log In
Log In
Log In
Upgrade
Zanidip Revenue
--
Log In
Log In
Log In
Upgrade
Zanipress Revenue
--
Log In
Log In
Log In
Upgrade
Urorec Revenue
--
Log In
Log In
Log In
Upgrade
Livazo Revenue
--
Log In
Log In
Log In
Upgrade
Seloken/Logimax Revenue
--
Log In
Log In
Log In
Upgrade
Eligard Revenue
--
Log In
Log In
Log In
Upgrade
Other Corporate Products Revenue
--
Log In
Log In
Log In
Upgrade
Drugs for Rare Diseases Revenue
--
Log In
Log In
Log In
Upgrade
OTC Revenue
--
Log In
Log In
Log In
Upgrade
Local Product Portfolios Revenue
--
Log In
Log In
Log In
Upgrade
Other Product Revenue
--
Log In
Log In
Log In
Upgrade

EBITDA

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Specialty & Primary Care EBITDA
516.45M524.44M
Log In
Log In
Log In
Upgrade
Rare Diseases EBITDA
392.73M341.33M
Log In
Log In
Log In
Upgrade

EBIT

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Specialty & Primary Care Operating Income
404.03M426.73M
Log In
Log In
Log In
Upgrade
Rare Diseases Operating Income
227.32M212.13M
Log In
Log In
Log In
Upgrade

Key Performance Indicators

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Specialty & Primary Care Like-For-Like Growth
5.70%
Log In
Log In
Log In
Upgrade
Rare Diseases Like-For-Like Growth
15.70%
Log In
Log In
Log In
Upgrade
Total Like-For-Like Growth
9.20%
Log In
Log In
Log In
Upgrade
Updated Jun 30, 2025. Data Source: Fiscal.ai.